Regardless of the mode of action of the FcγRIIB antibodies, our study provides a strong basis for the therapeutic application of FcγRIIB mAbs to promote immune responses against antigens, such as tumour-associated and non-self antigens. The gene discussed is FCGR2B; the disease is neoplasm.